About US
Contact us
-
Evonik announces price increaseEffective April 1, 2010, or as contract terms allow, Evonik Industries’ Household Care Business Line will increase the prices for all products marketed in Europe in the range of 10 %. These price incr2010/4/8
-
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 920100407(3).rar source: web of FDA2010/4/7
-
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 720100407(2).rar source:web of FDA2010/4/7
-
Guidance for Industry Q3C — Tables and List20100407(1).rar2010/4/7
-
EyeGate Pharma Completes Phase II Study of EGP-437 in Patients With Anterior UveitisEyeGate Pharma, a privately held venture-backed pharmaceutical company developing a non-invasive ocular drug delivery platform and ocular therapeutics, recently announced the completion of a P2010/4/6
-
Synairgen Initiates Phase II Trial With Inhaled Interferon Beta in Asthmatic SubjectsSynairgen plc, the respiratory drug discovery and development company with a particular focus on viral defense in asthma and chronic obstructive pulmonary disease (COPD), recently announced th2010/4/6
-
AMAG Pharmaceuticals & Takeda Pharmaceutical Company Announce Strategic Collaboration for FerahemeAMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited recently announced they have entered into a license, development, and commercialization agreement related to Feraheme (feru2010/4/6
-
ISP Presents the Principles of Biodegradability at Offshore West AfricaWayne, NJ USA 30 March 2010 – At the Offshore West Africa conference in Accra, Ghana, ISP presented its findings on a new polymeric composite proven to degrade 60% or more within 28 days. Th2010/4/2
-
Evonik announces price increaseEffective April 1, 2010, or as contract terms allow, Evonik Industries’ Household Care Business Line will increase the prices for all products marketed in Europe in the range of 10 %. These price incr2010/4/2
-
SciClone Announces Topline Results From Phase 2 Clinical Trial of SCV-07 for Prevention of Oral MucositisStudy Shows Signal of Delay to Onset of Severe OM in Higher Dose Group SciClone Pharmaceuticals, Inc. announced topline results from the company's phase 2 clinical trial of SCV-07 for the preventio2010/4/2